Table 1

Locations of extrahepatic primary cancers implicating hepatocellular carcinoma

Site of extrahepatic

primary cancer

Synchronous group (n = 22) Metachronous group (n = 46)

Total

(n = 68)

Head & neck 8 (36.4%) 15 (32.6%) 23 (33.8%)
  nasopharynx 2 (1R 1S) * 9 (9R) 11
  tonsil 1 (1C) 0 1
  larynx 1 (1C) 0 1
  vocal cord 1 (1S) 1 (1O) 2
  mouth 0 1 (1O) 1
  tongue 2 (1C1S) 1 (1O) 3
  gingiva 0 1 (1O) 1
  soft palate 1 (1S) 0 1
  thyroid gland 0 2 (2O) 2
Digestive system 8 (36.4%) 10 (21.7%) 18 (26.5%)
  esophagus 1 (1S) 4 (3O1C) 5
  stomach 2 (2O) 1 (1O) 3
  colorectal 5 (5O) 5 (5O) 10
Urogenital system 1 (4.5%) 5 (10.9%) 6 (8.8%)
  prostate 0 1 (1O) 1
  urinary bladder 1 (1O) 1 (1O) 2
  kidney 0 2 (1O1C) 2
  ovary 0 1 (1O) 1
Others 5 (22.7%) 16 (34.8%) 20 (29.4%)
  lung 2 (1C1S) 4 (1O2C 1R) 6
  breast 0 4 (4O) 4
  skin 1 (1O) 4 (4O) 5
Non Hodgkin’s lymphoma 1 (1R) 3 (3C) 3
  melanoma 0 1 (1O) 1
Soft tissue tumor 1 (1O) 0 0

* numbertreatment Treatment include: O operation; R radiotherapy; C chemotherapy; S supportive treatment.

The patient suffered the third primary malignancy, acute monocytic leukemia.

Zeng et al.

Zeng et al. BMC Cancer 2012 12:148   doi:10.1186/1471-2407-12-148

Open Data